Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate end points in trials: a scoping review

Manyara, AM; Davies, P; Stewart, D; Weir, CJ; Young, AE; Wells, V; Blazeby, J; Butcher, NJ; Bujkiewicz, S; Chan, A-W; Collins, GS; Dawoud, D; Offringa, M; Ouwens, M; Ross, JS; Taylor, RS; Ciani, O

Journal article : Review

Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate end points in trials: a scoping review

Abstract:: Objective
To synthesize the current literature on the use of surrogate end points, including definitions, acceptability, and limitations of surrogate end points and guidance for their design/reporting, into trial reporting items.
Study Design and Setting
Literature was identified through searching bibliographic databases (until March 1, 2022) and gray literature sources (until May 27, 2022). Data were thematically analyzed into four categories: (1) definitions, (2) acceptability, (3) limitations and challenges, and (4) guidance, and synthesized into reporting guidance items.
Results
After screening, 90 documents were included: 79% (n = 71) had data on definitions, 77% (n = 69) on acceptability, 72% (n = 65) on limitations and challenges, and 61% (n = 55) on guidance. Data were synthesized into 17 potential trial reporting items: explicit statements on the use of surrogate end point(s) and justification for their use (items 1–6); methodological considerations, including whether sample size calculations were informed by surrogate validity (items 7–9); reporting of results for composite outcomes containing a surrogate end point (item 10); discussion and interpretation of findings (items 11–14); plans for confirmatory studies, collecting data on the surrogate end point and target outcome, and data sharing (items 15–16); and informing trial participants about using surrogate end points (item 17).
Conclusion
The review identified and synthesized items on the use of surrogate end points in trials; these will inform the development of the Standard Protocol Items: Recommendations for Interventional Trials–SURROGATE and Consolidated Standards of Reporting Trials–SURROGATE extensions.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Manyara, A. M., Davies, P., Stewart, D., Weir, C. J., Young, A. E., Wells, V., Blazeby, J., Butcher, N. J., Bujkiewicz, S., Chan, A.-W., Collins, G. S., Dawoud, D., Offringa, M., Ouwens, M., Ross, J. S., Taylor, R. S., & Ciani, O. (2023). Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate end points in trials: a scoping review. Journal of Clinical Epidemiology, 160, 83–99.

MLA Style

Manyara, AM, et al. “Definitions, Acceptability, Limitations, and Guidance in the Use and Reporting of Surrogate End Points in Trials: a Scoping Review.” Journal of Clinical Epidemiology, vol. 160, 2023, pp. 83–99.

Chicago Style

Manyara, AM, P Davies, D Stewart, et al. 2023. “Definitions, Acceptability, Limitations, and Guidance in the Use and Reporting of Surrogate End Points in Trials: a Scoping Review.” Journal of Clinical Epidemiology 160: 83–99.
Print